ADEPTS (accelerated diagnosis of neuroendocrine and pancreatic tumours) and EDRA (early diagnosis research alliance)

Stephen Pereira; Julia Hippisley-Cox; John Timms; Justin Hsuan; Giuseppe Kito Fusai; Norman Williams; Eithne Costello; Bill  Greenhalf; Chiara Braconi; Melody Zhifang Ni; Robert van der Meer; Chris Macdonald

doi:10.1016/j.pan.2020.10.002

Abstract

Pancreatic neuroendocrine tumours (PNETs) and pancreatic adenocarcinoma (PDAC) are often diagnosed at an incurable stage when already spread outside the pancreas. If we could detect these tumours at an earlier stage, we could treat them with surgery so that more people would survive these diseases. To deliver early diagnosis for people with these cancers the Early Diagnosis Research Alliance (EDRA) commenced in 2019 and encompasses four complementary work packages: 1) Improve early symptom identification in patients with PNETs and PDAC, using CALIBER (UCL Institute of Health Informatics) and QResearch (U Oxford) resources; 2) Support blood biomarker discovery and validation programmes to develop ultrasensitive combined biomarker panels for early PNETs and PDAC; 3) Develop a large multicentre prospective blood sample resource in patients with non-specific but concerning symptoms (assessed by CDSTs: cancer decision support tools) attending endoscopy, clinics and rapid diagnostic centres; 4) Perform a stakeholder analysis, assess barriers to adoption and health economic studies to support early detection of pancreatic cancers. The EDRA includes the Accelerated Diagnosis of neuroEndocrine and Pancreaticobiliary TumourS (ADEPTS) Study (IRAS Number: 234637, NIHR Portfolio no. 7343). This study is a component of work package 3 and acts as the ethical framework for the national EDRA.

Original language	English
Pages (from-to)	e14
Number of pages	1
Journal	Pancreatology
Volume	20
Issue number	8
Early online date	23 Nov 2020
DOIs	https://doi.org/10.1016/j.pan.2020.10.002
Publication status	Published - 1 Dec 2020
Event	The London Pancreas Workshop 2020: A forum for state-of-the-art clinical and basic research in pancreatic cancer - Barts Cancer Institute, Queen Mary University of London, London, United Kingdom Duration: 11 Sept 2020 → 11 Sept 2020 https://www.bartscancer.london/event/the-london-pancreas-workshop-2020/

Keywords

pancreatic ductal adenocarcinoma
pancreatic neuroendocrine tumours
ADEPTS
Early Diagnosis Research Alliance
biomarkers
early detection of cancer

Access to Document

10.1016/j.pan.2020.10.002Licence: Unspecified

1 Finished

ADEPTS: Accelerated Diagnosis of neuroEndocrine and Pancreatic TumourS
van der Meer, R. (Principal Investigator) & Morton, A. (Co-investigator)
Pancreatic Cancer UK
1/11/18 → 31/10/22
Project: Research

1 Abstract
1 Poster
1 Conference abstract

Cost-benefit analysis of biomarker-driven early detection of pancreatic cancer in individuals with new-onset diabetes
Stefanova, I., Thompson, N., Stott, M., Oldfield, L., Hanson, R., van der Meer, R., Palmer, D., Greenhalf, W., Halloran, C. & Costello, E., 27 Jun 2024. 1 p.
Research output: Contribution to conference › Poster › peer-review

Open Access
File
Downstaging the most deadly cancer is cost-effective. Can we achieve a cost-effective early diagnosis?
Zamora, B., Ney, A., van der Meer, R., Thompson, N., Pereira, S. & Ni, M., 2 Dec 2022. 1 p.
Research output: Contribution to conference › Abstract › peer-review
Recruitment pathways in the UK early detection initiative (UK-EDI) for pancreatic cancer study
Stott, M., Hanson, R., Oldfield, L., Greenhalf, W., van der Meer, R., Alison, L., Christiansen, P., Ghaneh, P., Purewal, T., Palmer, D., Jackson, R., Halloran, C. & Costello, E., 1 Jul 2021, In: Pancreatology. 21, Supplement 1, p. S109 1 p., P.248.
Research output: Contribution to journal › Conference abstract › peer-review

Open Access
File
15 Downloads (Pure)

1 Participation in workshop, seminar, course
1 Invited talk

Data Science in understanding cancer: hands-on examples
van der Meer, R. (Invited speaker)
7 Feb 2023
Activity: Talk or presentation types › Invited talk
Meeting of Scientific Advisory Board of Pancreatic Cancer UK and Launch of the ADEPTS study
Pereira, S. (Invited speaker), Hippisley-Cox, J. (Invited speaker), Hsuan, J. (Invited speaker), Timms, J. (Invited speaker), Braconi, C. (Invited speaker), van der Meer, R. (Invited speaker) & Zhifang Ni, M. (Invited speaker)
26 Jun 2018 → 27 Jun 2018
Activity: Participating in or organising an event types › Participation in workshop, seminar, course

Cite this

@article{90b9287fa1764b8d892e665d90d06b30,

title = "ADEPTS (accelerated diagnosis of neuroendocrine and pancreatic tumours) and EDRA (early diagnosis research alliance)",

abstract = "Pancreatic neuroendocrine tumours (PNETs) and pancreatic adenocarcinoma (PDAC) are often diagnosed at an incurable stage when already spread outside the pancreas. If we could detect these tumours at an earlier stage, we could treat them with surgery so that more people would survive these diseases. To deliver early diagnosis for people with these cancers the Early Diagnosis Research Alliance (EDRA) commenced in 2019 and encompasses four complementary work packages: 1) Improve early symptom identification in patients with PNETs and PDAC, using CALIBER (UCL Institute of Health Informatics) and QResearch (U Oxford) resources; 2) Support blood biomarker discovery and validation programmes to develop ultrasensitive combined biomarker panels for early PNETs and PDAC; 3) Develop a large multicentre prospective blood sample resource in patients with non-specific but concerning symptoms (assessed by CDSTs: cancer decision support tools) attending endoscopy, clinics and rapid diagnostic centres; 4) Perform a stakeholder analysis, assess barriers to adoption and health economic studies to support early detection of pancreatic cancers. The EDRA includes the Accelerated Diagnosis of neuroEndocrine and Pancreaticobiliary TumourS (ADEPTS) Study (IRAS Number: 234637, NIHR Portfolio no. 7343). This study is a component of work package 3 and acts as the ethical framework for the national EDRA.",

keywords = "pancreatic ductal adenocarcinoma, pancreatic neuroendocrine tumours, ADEPTS, Early Diagnosis Research Alliance, biomarkers, early detection of cancer",

author = "Stephen Pereira and Julia Hippisley-Cox and John Timms and Justin Hsuan and Fusai, {Giuseppe Kito} and Norman Williams and Eithne Costello and Bill Greenhalf and Chiara Braconi and Ni, {Melody Zhifang} and {van der Meer}, Robert and Chris Macdonald",

year = "2020",

month = dec,

day = "1",

doi = "10.1016/j.pan.2020.10.002",

language = "English",

volume = "20",

pages = "e14",

journal = "Pancreatology",

issn = "1424-3903",

number = "8",

note = "The London Pancreas Workshop 2020 : A forum for state-of-the-art clinical and basic research in pancreatic cancer ; Conference date: 11-09-2020 Through 11-09-2020",

url = "https://www.bartscancer.london/event/the-london-pancreas-workshop-2020/",

}

TY - JOUR

T1 - ADEPTS (accelerated diagnosis of neuroendocrine and pancreatic tumours) and EDRA (early diagnosis research alliance)

AU - Pereira, Stephen

AU - Hippisley-Cox, Julia

AU - Timms, John

AU - Hsuan, Justin

AU - Fusai, Giuseppe Kito

AU - Williams, Norman

AU - Costello, Eithne

AU - Greenhalf, Bill

AU - Braconi, Chiara

AU - Ni, Melody Zhifang

AU - van der Meer, Robert

AU - Macdonald, Chris

PY - 2020/12/1

Y1 - 2020/12/1

N2 - Pancreatic neuroendocrine tumours (PNETs) and pancreatic adenocarcinoma (PDAC) are often diagnosed at an incurable stage when already spread outside the pancreas. If we could detect these tumours at an earlier stage, we could treat them with surgery so that more people would survive these diseases. To deliver early diagnosis for people with these cancers the Early Diagnosis Research Alliance (EDRA) commenced in 2019 and encompasses four complementary work packages: 1) Improve early symptom identification in patients with PNETs and PDAC, using CALIBER (UCL Institute of Health Informatics) and QResearch (U Oxford) resources; 2) Support blood biomarker discovery and validation programmes to develop ultrasensitive combined biomarker panels for early PNETs and PDAC; 3) Develop a large multicentre prospective blood sample resource in patients with non-specific but concerning symptoms (assessed by CDSTs: cancer decision support tools) attending endoscopy, clinics and rapid diagnostic centres; 4) Perform a stakeholder analysis, assess barriers to adoption and health economic studies to support early detection of pancreatic cancers. The EDRA includes the Accelerated Diagnosis of neuroEndocrine and Pancreaticobiliary TumourS (ADEPTS) Study (IRAS Number: 234637, NIHR Portfolio no. 7343). This study is a component of work package 3 and acts as the ethical framework for the national EDRA.

AB - Pancreatic neuroendocrine tumours (PNETs) and pancreatic adenocarcinoma (PDAC) are often diagnosed at an incurable stage when already spread outside the pancreas. If we could detect these tumours at an earlier stage, we could treat them with surgery so that more people would survive these diseases. To deliver early diagnosis for people with these cancers the Early Diagnosis Research Alliance (EDRA) commenced in 2019 and encompasses four complementary work packages: 1) Improve early symptom identification in patients with PNETs and PDAC, using CALIBER (UCL Institute of Health Informatics) and QResearch (U Oxford) resources; 2) Support blood biomarker discovery and validation programmes to develop ultrasensitive combined biomarker panels for early PNETs and PDAC; 3) Develop a large multicentre prospective blood sample resource in patients with non-specific but concerning symptoms (assessed by CDSTs: cancer decision support tools) attending endoscopy, clinics and rapid diagnostic centres; 4) Perform a stakeholder analysis, assess barriers to adoption and health economic studies to support early detection of pancreatic cancers. The EDRA includes the Accelerated Diagnosis of neuroEndocrine and Pancreaticobiliary TumourS (ADEPTS) Study (IRAS Number: 234637, NIHR Portfolio no. 7343). This study is a component of work package 3 and acts as the ethical framework for the national EDRA.

KW - pancreatic ductal adenocarcinoma

KW - pancreatic neuroendocrine tumours

KW - ADEPTS

KW - Early Diagnosis Research Alliance

KW - biomarkers

KW - early detection of cancer

U2 - 10.1016/j.pan.2020.10.002

DO - 10.1016/j.pan.2020.10.002

M3 - Conference abstract

SN - 1424-3903

VL - 20

SP - e14

JO - Pancreatology

JF - Pancreatology

IS - 8

T2 - The London Pancreas Workshop 2020

Y2 - 11 September 2020 through 11 September 2020

ER -

ADEPTS (accelerated diagnosis of neuroendocrine and pancreatic tumours) and EDRA (early diagnosis research alliance)

Abstract

Keywords

Access to Document

Fingerprint

Projects

ADEPTS: Accelerated Diagnosis of neuroEndocrine and Pancreatic TumourS

Research output

Cost-benefit analysis of biomarker-driven early detection of pancreatic cancer in individuals with new-onset diabetes

Downstaging the most deadly cancer is cost-effective. Can we achieve a cost-effective early diagnosis?

Recruitment pathways in the UK early detection initiative (UK-EDI) for pancreatic cancer study

Activities

Data Science in understanding cancer: hands-on examples

Meeting of Scientific Advisory Board of Pancreatic Cancer UK and Launch of the ADEPTS study

Cite this